以岭药业: 关于收到药品注册申请受理通知书的公告

Group 1 - The core point of the announcement is that Shijiazhuang Yiling Pharmaceutical Co., Ltd. has received a formal acceptance notice from the National Medical Products Administration for the new drug registration application of "Children's Lianhua Qinggan Granules" [1] - The application is for the domestic production drug registration license, with the acceptance number CXZS2500034 [1] - The drug is an innovative traditional Chinese medicine developed by the company, aimed at treating acute upper respiratory infections in children, with symptoms including fever, nasal congestion, sore throat, cough, and muscle aches [1] Group 2 - The acceptance of the drug registration application will lead to a series of evaluations and inspections by the National Medical Products Administration, which introduces uncertainty regarding the completion time and approval results [1] - The company emphasizes that the acceptance of the registration application will not have an immediate impact on its recent performance [1]